In the face of the unknown, two cancer center leaders discuss planning for the future, recovering from setbacks, and holding on to what they still have.
As NIH and NCI funding is negotiated in Congress, Paul W. Thurman felt compelled to crunch some numbers. He compared the U.S.’s cumulative funding for NCI to the funding slated for ICE—the latter of which vastly outweighs the former—and asked whether the funding priorities of the federal government are properly representing the nation’s mortality.
When Robert A. Winn was named director of the University of Illinois Cancer Center in 2015, he knew that the skills required to be a successful cancer center director were very different from the skills he drew upon to be a successful scientist. So, he formed an informal, personal mentorship team.
Gardiner Harris, acclaimed health care and pharma journalist, on his New York Times bestselling book
In his new book, “No More Tears: The Dark Secrets of Johnson & Johnson,” Gardiner Harris, who was previously the public health and pharmaceutical business reporter for The New York Times, talks about the history of the overuse of red blood cell growth factors in oncology.
Phil and Penny Knight made a record-setting $2 billion gift to OHSU Knight Cancer Institute.
In the last three years of her life, Andrea Werblin Reid wrote 150 poems on living with ovarian cancer and end of life. Werblin Reid died of ovarian cancer in 2022. Her third collection of poetry, “To See Yourself As You Vanish,” will be published Sept. 9.
Mary Beckerle, a whitewater kayaker, has advice for all the folks in the cancer field: never catastrophize, never panic.
While doing somewhat-routine reporting on this year’s Senate Appropriations Committee bills, Paul Goldberg, editor and publisher of The Cancer Letter, quickly realized that he was seeing a full bipartisan rejection of President Donald J. Trump’s plan to defund and therefore dismantle biomedical research in the United States.
Do multi-cancer detection tests provide a net benefit? NCI aims to answer this question, beginning with the Vanguard feasibility trial which recently started accruing patients.
NIH has announced it will stop issuing funding opportunities solely dedicated to animal models, but has not published any formal guidance related to the announcement, and researchers are unclear on when or whether further policy materials are to be expected.
